Posted by Michael Wonder on 18 Feb 2017
Health Canada approves Otsuka and Lundbeck's Rexulti (brexpiprazole) as a treatment for schizophrenia in adults
17 February 2017 - Otsuka and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for Rexulti (brexpiprazole) for the treatment of schizophrenia in adults.
Rexulti was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become commercially available in Canada this spring.
